Analgesics are medicines used to reduce or relieve pain without necessarily treating the underlying cause of that pain. Pain is a complex sensory and emotional experience produced through interactions between tissue signals, peripheral nerves, spinal processing and the brain, so different Analgesics act at different points in this system. The category includes medicines with very different pharmacological properties, ranging from non-opioid medicines such as paracetamol to non-steroidal anti-inflammatory drugs and opioid medicines.
Some medicines developed primarily for other indications, including certain antidepressants and anticonvulsants, can also have analgesic effects in particular pain conditions, although their mechanisms and clinical uses differ from those of conventional painkillers. Analgesics can be used for acute pain following injury or surgery, chronic pain associated with persistent disease, cancer-related pain and particular neuropathic pain syndromes. The appropriate medicine depends on pain type, intensity, duration, cause, comorbidities, other medicines and the potential for adverse effects or dependence.
Analgesics differ according to the biological processes they influence. Paracetamol provides analgesic and antipyretic effects but has comparatively little peripheral anti-inflammatory activity at standard therapeutic doses. Non-steroidal anti-inflammatory drugs reduce prostaglandin synthesis by inhibiting cyclooxygenase enzymes and are particularly useful when inflammation contributes to pain. Opioids act primarily through opioid receptors in the nervous system and can reduce the perception and emotional response to pain while also producing sedation and respiratory depression.
Local anaesthetic medicines differ again because they block voltage-gated sodium channels and temporarily prevent nerve conduction in a targeted region. Medicines used for neuropathic pain may reduce abnormal neuronal excitability or alter neurotransmitter signalling rather than simply suppressing inflammatory pain. These distinctions explain why a medicine effective for one form of pain may provide little benefit for another and why increasing the dose of an ineffective mechanism is not necessarily an appropriate strategy.
Pain can be broadly described according to mechanisms including nociceptive, inflammatory and neuropathic components, although real patients frequently have mixed pain. Nociceptive pain arises from activation of sensory pathways by actual or threatened tissue damage, while inflammatory pain involves mediators that sensitise pain pathways during inflammation. Neuropathic pain results from injury or disease affecting somatosensory pathways and can involve burning, electric, shooting or abnormal sensory experiences. Analgesic selection should therefore consider mechanism rather than intensity alone.
A mild inflammatory pain may respond well to a non-steroidal anti-inflammatory drug, while neuropathic pain may respond better to a medicine affecting neuronal signalling. Severe acute pain may require an opioid under appropriate supervision, but severity does not by itself establish that opioids are the best long-term option. The distinction between symptom control and treatment of the underlying disease is also important because an Analgesic can reduce pain while leaving the causal pathology unchanged.
Safety profiles are a major determinant of Analgesic selection. Paracetamol is generally well tolerated at appropriate doses but excessive total exposure can cause severe liver injury, particularly when multiple products containing the same ingredient are inadvertently combined. Non-steroidal anti-inflammatory drugs can cause gastrointestinal irritation or bleeding, kidney injury, fluid retention and adverse cardiovascular effects, with risks varying by medicine and patient characteristics.
Opioids can cause constipation, nausea, sedation, impaired alertness, respiratory depression and tolerance, and repeated use can result in physical dependence and opioid use disorder. The risks of any Analgesic depend on dose, duration, interactions, age, organ function and underlying disease. Combining medicines may sometimes provide complementary analgesia and reduce reliance on a single drug, but combinations can also duplicate ingredients or increase toxicity.
Acute and chronic pain require different therapeutic considerations. Acute pain often has a relatively identifiable precipitating cause and may improve as tissue healing occurs, whereas chronic pain can persist beyond the expected period of tissue healing and may involve changes in nervous-system processing. Long-term Analgesic use therefore requires periodic reassessment of benefit, adverse effects, functional outcomes and the continuing relevance of the original diagnosis.
Pain intensity scores are useful but do not capture every clinically important outcome; sleep, mobility, work, mood and ability to perform daily activities can also matter. Chronic pain management may involve medicines alongside physical rehabilitation, psychological approaches, treatment of the underlying disease and other interventions. An Analgesic that produces a numerical reduction in pain but causes substantial sedation or functional impairment may not provide an overall useful outcome.
Opioid Analgesics occupy a particularly important and complex position within pain medicine. Their ability to produce powerful analgesia results from activation of opioid receptors in central and peripheral nervous systems, but the same receptor activity can produce respiratory depression, constipation and other adverse effects. Tolerance can develop to some effects, while physical dependence can occur with repeated exposure and means that abrupt discontinuation after prolonged use can cause withdrawal.
These phenomena are distinct from addiction, although opioid use disorder can develop in some people. Opioids may be appropriate for certain acute, postoperative, palliative or cancer-related pain situations, but their use requires careful assessment of benefits and risks. Long-term treatment of chronic non-cancer pain requires particular attention to functional benefit, adverse effects and the possibility that escalating doses may increase harm without producing proportionate improvement.
Analgesics can interact with other medicines and physiological conditions in clinically significant ways. Sedating medicines can compound opioid-related impairment, while medicines affecting kidney function can increase risks associated with certain non-steroidal anti-inflammatory drugs. Anticoagulant therapy can increase concern about bleeding when combined with medicines that impair platelet function or damage gastrointestinal mucosa. Liver disease can alter the safety margin of medicines metabolised hepatically, while kidney disease can affect elimination of several analgesic agents.
Older adults may be particularly vulnerable to falls, confusion, kidney injury or gastrointestinal complications. Children require age- and weight-appropriate dosing and formulation. These factors illustrate why analgesic choice cannot be reduced to a simple hierarchy of “strong” and “weak” painkillers; clinical suitability depends on the interaction between the medicine, the pain mechanism and the person receiving it.
The history of Analgesics includes traditional plant-derived substances, development of modern synthetic medicines, discovery of opioid receptors and increasing understanding of pain neurobiology. Modern analgesic practice increasingly emphasises mechanism-based treatment, multimodal strategies and minimising avoidable adverse effects. No Analgesic is universally effective for every pain condition, and complete elimination of pain is not always achievable or necessary for meaningful functional improvement.
Common misconceptions include assuming that stronger analgesia is always better, that pain relief proves an injury has healed, or that all pain responds to the same pharmacological mechanism. Appropriate use involves identifying the cause and type of pain, selecting a medicine whose mechanism fits the clinical problem, using an appropriate dose and duration, monitoring effectiveness and harm, and addressing the underlying condition whenever possible.
